BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27075079)

  • 21. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chemotherapy for malignant tumors: problems and prospects].
    Orlova RV; Vaizyan RI; Ivanova AK; Tikhonova EK; Zorina EY
    Vopr Onkol; 2015; 61(2):244-51. PubMed ID: 26087606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy in the treatment of castration-resistant prostate cancer.
    Derleth CL; Yu EY
    Oncology (Williston Park); 2013 Jul; 27(7):620-8. PubMed ID: 23977754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer drug resistance: A fleet to conquer.
    Hussain S; Singh A; Nazir SU; Tulsyan S; Khan A; Kumar R; Bashir N; Tanwar P; Mehrotra R
    J Cell Biochem; 2019 Sep; 120(9):14213-14225. PubMed ID: 31037763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The niche under siege: novel targets for metastasis therapy.
    Santamaria-Martínez A; Huelsken J
    J Intern Med; 2013 Aug; 274(2):127-36. PubMed ID: 23253195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical studies in oncology--a challenge for clinical and academic pathology].
    Röcken C
    Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
    [No Abstract]   [Full Text] [Related]  

  • 28. [Precise pathological and molecular diagnosis is the premise of relevant anti-cancer targeted therapy].
    Zheng J
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):433-4. PubMed ID: 17845751
    [No Abstract]   [Full Text] [Related]  

  • 29. The tumour trail left in blood.
    Chi KR
    Nature; 2016 Apr; 532(7598):269-71. PubMed ID: 27075102
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeted therapy: overcoming drug resistance with clinical cancer genome.
    Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
    [No Abstract]   [Full Text] [Related]  

  • 31. Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.
    Long KB; Collier AI; Beatty GL
    Mol Immunol; 2019 Jun; 110():3-12. PubMed ID: 29273393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise.
    Kashkar H
    Clin Cancer Res; 2010 Sep; 16(18):4496-502. PubMed ID: 20682709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
    Ramos P; Bentires-Alj M
    Oncogene; 2015 Jul; 34(28):3617-26. PubMed ID: 25263438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy for thyroid cancer: striking the survival signaling.
    Vitale M
    J Clin Endocrinol Metab; 2011 Apr; 96(4):936-8. PubMed ID: 21474689
    [No Abstract]   [Full Text] [Related]  

  • 36. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
    Bryant G; Wang L; Mulholland DJ
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
    Rosell R; Karachaliou N; Wolf J; Ou SH
    Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
    [No Abstract]   [Full Text] [Related]  

  • 40. EGFR-targeted therapy.
    Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
    Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.